Li Youjia, Dong Mengru, Liao Shengyu, Jiang Yu, Niu Yingjie, Huang Yiqin, Fu Wei, Chen Debo, Hong Zhipeng
Department of Ultrasound, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou, 362000, Fujian Province, China.
Standardization Training Office, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou, 362000, Fujian Province, China.
Sci Rep. 2025 May 27;15(1):18485. doi: 10.1038/s41598-025-01353-z.
This study evaluates the effectiveness of ultrasound-guided fine needle aspiration biopsy (US-FNAB) in assessing additional positive axillary lymph node (ALN) metastasis following sentinel lymph node biopsy (SLNB) in clinically ALN-negative or N1 cases, aiming to refine patient management. A multi-center, retrospective analysis included 7617 patients with cT1-2 and cN0-1, who underwent US-FNAB for ALN and proceeding to SLNB or axillary lymph node dissection (ALND). Metastatic patterns were assessed, particularly focusing on correlations with positive FNAB results and additional ALN metastasis found during ALND, with statistical significance evaluated. Of those undergoing SLNB, 97.5% exhibited macrometastasis. In the SLNB-only group, 2.4% had 3 and more than 3 positive lymph node, compared to 19.2% in the SLNB & ALND group (P < 0.01). Among ALND patients, 63.3% had positive nodes, significantly higher in those with positive FNAB (91.9% vs. 22.8%, P < 0.001). Additionally, 40.9% were found to have additional positive ALNs in patients who underwent ALND following positive SLNB, with rates significantly higher in those with positive FNAB (60.3% vs. 35.4%, P < 0.001). LVI positivity, pT2-3, SLNR > 50% and positive FNAB were independent predictors of additional ALN metastasis in patients undergoing ALND after positive SLNB (P < 0.05). The proportion of additional positivity escalated with the number of positive SLNs. US-FNAB significantly improves the detection of additional ALN metastasis, guiding more effective strategy for ALN surgical decision-making. Our findings support the incorporation of US-FNAB into clinical practice to improve patient stratification and optimize treatment outcomes in early-stage breast cancer management.
本研究评估超声引导下细针穿刺活检(US-FNAB)在评估临床腋窝淋巴结阴性或N1病例前哨淋巴结活检(SLNB)后额外的腋窝淋巴结阳性(ALN)转移情况中的有效性,旨在优化患者管理。一项多中心回顾性分析纳入了7617例cT1-2和cN0-1患者,这些患者接受了针对ALN的US-FNAB,随后进行了SLNB或腋窝淋巴结清扫术(ALND)。评估了转移模式,特别关注与FNAB阳性结果以及ALND期间发现的额外ALN转移的相关性,并评估了统计学意义。在接受SLNB的患者中,97.5%表现为大转移。仅接受SLNB的组中,2.4%有3个及以上阳性淋巴结,而在SLNB联合ALND组中为19.2%(P<0.01)。在接受ALND的患者中,63.3%有阳性淋巴结,FNAB阳性患者中的比例显著更高(91.9%对22.8%,P<0.001)。此外,在SLNB阳性后接受ALND的患者中,40.9%被发现有额外的阳性ALN,FNAB阳性患者中的比例显著更高(60.3%对35.4%,P<0.001)。淋巴管浸润阳性、pT2-3、前哨淋巴结转移率>50%和FNAB阳性是SLNB阳性后接受ALND患者额外ALN转移的独立预测因素(P<0.05)。额外阳性的比例随着阳性前哨淋巴结数量的增加而升高。US-FNAB显著提高了对额外ALN转移的检测,为ALN手术决策指导了更有效的策略。我们的研究结果支持将US-FNAB纳入临床实践,以改善早期乳腺癌管理中的患者分层并优化治疗结果。